arrow
S

Shiuh-Wen Luoh

Portland VA Healthcare System
H指数:29
被引数:3,114

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Increasing value in the Veterans Affairs Healthcare System (VA) with precision health: a continuing landmark collaboration with the Department of Energy

通过精准健康提升退伍军人事务部医疗系统(VA)的价值:与能源部持续的地标性合作

2026-04-250
PRE
A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality
2022-11-1511
OAAI
Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19
2022-06-095
OA
Impact of Coronavirus Disease 2019 (COVID-19) Severity on Long-term Events in United States Veterans Using the Veterans Affairs Severity Index for COVID-19 (VASIC)
2022-05-056
OA
A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program
2022-04-2813
OAAI
A randomized-controlled trial comparing supervised aerobic training to resistance training followed by unsupervised exercise on physical functioning in older breast cancer survivors

一项随机对照试验,比较了有监督的有氧训练与阻力训练,然后进行无监督的运动对老年乳腺癌幸存者的身体功能的影响

2022-03-0120
OAAI
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q (vol 30, pg 1821, 2019)
2021-08-010
OAAI
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
2019-11-0197
OAAI
Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

II期研究评估sagopilone (zk-epo) 在化疗后进展的转移性乳腺癌患者中的疗效和安全性

2010-08-1017
PREAI